Top

Published in:

01-06-2014 | R&D Insight Report

Luseogliflozin: First Global Approval

Authors: Anthony Markham, Shelley Elkinson

Published in: Drugs | Issue 8/2014

Abstract

Luseogliflozin [Lusefi^® (Japan)] is an orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor developed by Taisho Pharmaceutical for the treatment of patients with type 2 diabetes mellitus (T2DM). The drug has received its first global approval for this indication in Japan, either as monotherapy or in combination with other antihyperglycaemic agents. This article summarises the milestones in the development of luseogliflozin leading to this first approval for the treatment of T2DM.

Abdul-Ghani MA, Norton L, DeFronzo RA. Efficacy and safety of SGLT2 inhibitors in the treatment of type 2 diabetes mellitus. Curr Diabetes Rep. 2012;12(3):230–8.CrossRef

Vasilakou D, Karagiannis T, Athanasiadou E, et al. Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis. Ann Intern Med. 2013;159(4):262–74.PubMedCrossRef

Taisho P. Acquisition of Manufacturing and Marketing Approval in Japan for SGLT2 Inhibitor Lusefi(Rm) Tablets 2.5 mg and Lusefi(Rm) Tablets 5 mg [media release. http://www.taisho-holdings.co.jp]. 24 Mar 2014.

Novartis. Lusefi (luseogliflozin): Japanese prescribing information [In Japanese]. 2014. http://medical.taishotoyama.co.jp/cgi-bin/index2_n.cgi?mode=sel&rows=86&caut=tenp&page=/data/tenp/pdf/tenp_lsf.pdf. Accessed 11 May 2014.

Taisho Pharmaceutical Holdings Co L. Signing of Domestic Sales Rights Licensing Agreement Regarding SGLT2 Inhibitor TS-071 [media release]. http://www.taisho-holdings.co.jp. 30 Nov 2012.

Kakinuma H, Oi T, Hashimoto-Tsuchiya Y, et al. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. J Med Chem. 2010;53(8):3247–61.PubMedCrossRef

Teisuke T, Kozakai A, Kojima N, et al. Long-term treatment of TS-071, a novel, potent and selective SGLT2 inhibitor, improves hyperglycaemia and prevents the loss of beta cell in diabetic mice. Diabetologia. 2011;54:S345.

Yamamoto K, Uchida S, Kitano K, et al. TS-071 is a novel, potent and selective renal sodium-glucose cotransporter 2 (SGLT2) inhibitor with anti-hyperglycaemic activity. Br J Pharmacol. 2011;164(1):181–91.PubMedCentralPubMedCrossRef

Uchida S, Takahashi T, Tomoike H, et al. TS-071, a novel, potent and selective SGLT2 inhibitor, induces weight loss and a reduction in adipocyte size in diet-induced obese rats. Diabetes. 2011;60:A274.CrossRef

10.

Sasaki T, Seino Y, Fukatsu A, et al. Safety, pharmacokinetics, and pharmacodynamics of single and multiple luseogliflozin dosing in healthy Japanese males: a randomized, single-blind, placebo-controlled trial. Adv Ther. 2014;31(3):345–61.PubMedCentralPubMedCrossRef

11.

Sasaki T, Seino Y, Fukatsu A, et al. TS-071, a novel potent and highly selective renal sodium-glucose co- transporter 2 (SGLT2) inhibitor, increases urinary glucose excretion and reduces plasma glucose levels in Japanese patients with type 2 diabetes mellitus. 47th Annual Meeting of the European Association for the Study of Diabetes. 2011:abstr. 846.

12.

Morrow LA, Guttierrez MJ, Tanaka Y, et al. Luseogliflozin (TS-071), a novel, potent, and selective inhibitor of SGLT2 is safe and well-tolerated in type 2 diabetes mellitus and showed dosedependent PK/PD in both US/Japanese ethnicities. Diabetologia. 2012;55:S304.

13.

Haneda M, Seino Y, Sasaki T, et al. The effect of luseogliflozin (TS-071), a selective SGLT2 inhibitor, on pharmacodynamics and pharmacokinetics in Japanese type 2 diabetic subjects with renal impairment. Diabetes. 2012;61:A273.

14.

Sasaki T, Seino Y, Samukawa Y, et al. Effects of gender and age on the pharmacokinetics and pharmacodynamics of luseogliflozin (TS-071), a selective SGLT2 inhibitor. Diabetes. 2012;61:A275.

15.

Nakai Y, Mutoh M. Luseogliflozin (TS-071) a novel, potent and selective sglt2 inhibitor, did not affect the PK of several oral diabetic agents in clinical. Diabetes. 2012;61:A607.

16.

Inagaki N, Seino Y, Sasaki T, et al. Luseogliflozin, a selective SGLT2 inhibitor, added on to glimepiride for 52 weeks improves glycaemic control with no major hypoglycaemia in Japanese type 2 diabetes patients. 49th Annual Meeting of the European Association for the Study of Diabetes. 2013:abstr. 184.

17.

Haneda M, Seino Y, Sasaki T, et al. Luseogliflozin, a SGLT2 inhibitor, as add-on therapy to 5 types of oral antidiabetic drugs improves glycaemic control and reduces body weight in Japanese patients with type 2 diabetes mellitus. 49th Annual Meeting of the European Association for the Study of Diabetes. 2013:abstr. 957.

18.

Seino Y, Sasaki T, Fukatsu A, et al. Luseogliflozin, a selective SGLT2 inhibitor, improves glycemic control as monotherapy in Japanese patients with T2DM. World Diabetes Congress 2013. 2013:abstr. P-1472.

19.

Seino Y, Sasaki T, Fukatsu A, et al. Efficacy and safety of luseogliflozin as monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, phase 3 study. Curr Med Res Opin. 2014. doi:10.1185/03007995.2014.912983.

20.

Seino Y, Sasaki T, Fukatsu A, et al. Dose-finding study of luseogliflozin in Japanese patients with type 2 diabetes mellitus: a 12-week, randomized, double-blind, placebo-controlled, phase II study. Curr Med Res Opin. 2014. doi:10.1185/03007995.2014.909390:1-14.

21.

Seino Y, Sasaki T, Fukatsu A, et al. TS-071, a Novel and Selective SGLT2 Inhibitor, Improved Glycemic Control and Decreased Body Weight in 12-Week Study of Japanese Patients with Type 2 Diabetes Mellitus. 71st Annual Scientific Sessions of the American Diabetes Association. 2011:abstr. 0998-P.

22.

Seino Y, Sasaki T, Fukatsu A, et al. TS-071, a novel and selective SGLT2 inhibitor, improved glycemic control and decreased body weight in 12-week study of Japanese patients with type 2 diabetes mellitus. Diabetes. 2011;60:A274.

23.

Seino Y, Sasaki T, Fukatsu A, et al. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycaemic control and lowers body weight in a 12-week study in Japanese patients with type 2 diabetes mellitus. 48th Annual Meeting of the European Association for the Study of Diabetes. 2012:abstr. 740.

Title: Luseogliflozin: First Global Approval
Authors: Anthony Markham
Shelley Elkinson
Publication date: 01-06-2014
Publisher: Springer International Publishing
Published in: Drugs / Issue 8/2014
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-014-0230-8

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Luseogliflozin: First Global Approval

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 8/2014

Pharmacokinetics and Pharmacodynamics of Antifungals in Children: Clinical Implications

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

First-Line and Maintenance Therapy for Ovarian Cancer: Current Status and Future Directions

Next-Generation Phosphate Binders: Focus on Iron-Based Binders

Lithium in the Treatment of Major Depressive Disorder

Tofogliflozin: First Global Approval